Form 13-F position report

IRONWOOD PHARMACEUTICALS IN

Reported by Virtus Investment Advisers Inc

IRWD 0.75 06/15/24 CUSIP 46333XAF5 Manager CIK 0000019481

Reported 0 shares, down 42,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-12-31 43785
2024-03-31 41659
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

3 quarters
Quarterly reported position history for IRONWOOD PHARMACEUTICALS IN held by Virtus Investment Advisers Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -42,000 (-100.0%) 0 $0 2024-08-14
Q1 2024 Unchanged 42,000 0 (0.0%) 0.03% $41,659 2024-05-16
Q4 2023 New 42,000 +42,000 (0.0%) 0.03% $43,785 2024-02-15

Who else reported the position

18 managers reported IRONWOOD PHARMACEUTICALS IN for Q2 2024.

Managers reporting IRONWOOD PHARMACEUTICALS IN in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
LAZARD ASSET MANAGEMENT LLC Reduced 0 -18,738,000 0 $0 2 qtrs
Verition Fund Management LLC Reduced 0 -5,833,000 0 $0 2 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -2,000,000 0 $0 2 qtrs
BANK OF MONTREAL Reduced 0 -8,500,000 0 $0 5 qtrs
Citigroup Inc Reduced 0 -2,352,000 0 $0 14 qtrs
CAPSTONE INVESTMENT ADVISORS LLC Unchanged 0 0 0 $0 16 qtrs
TENOR CAPITAL MANAGEMENT Co L P Reduced 0 -37,375,000 0 $0 16 qtrs
GROUPAMA ASSET MANAGMENT Reduced 0 -1,000,000 0 $0 2 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 16 qtrs
Calamos Advisors LLC Reduced 0 -5,000 0 $0 16 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
NOTE 0.750% 6/1

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.